Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Advertisement
- Data Monitoring Committee (DMC) determines RG7128, a first-in-class nucleoside analog polymerase inhibitor continues to have acceptable safety profile
Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
